Neurotoxicity Syndromes
Symptoms, Doctors, Treatments, Advances & More

Neurotoxicity Syndromes Overview

Save information for later
Sign Up

Learn About Neurotoxicity Syndromes

What is the definition of Neurotoxicity Syndromes?
Neurotoxicity syndromes is a term used to describe neurological disorders caused by exposure to toxic substances. Neurotoxicity may occur after exposure to substances such as drugs; chemotherapy; radiation; heavy metals, such as lead or mercury; pesticides; industrial and/or cleaning solvents; petroleum-based products and dispersants; some foods and food additives; and some naturally occurring environmental substances. Exposure to such toxic substances disrupts or kills nerve cells, or neurons, that are responsible for brain and nervous system functions. Neurotoxicity may occur by exposure to toxic substances through ingestion, injection, inhalation, spray, direct skin exposure, or other methods.
What are the symptoms of Neurotoxicity Syndromes?
Symptoms of neurotoxicity may be immediate or delayed. Symptoms of neurotoxicity can include weakness, numbness, headache, memory loss, visual disturbances, cognitive difficulties, behavioral changes, and loss of sexual function, among others.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Neurotoxicity Syndromes?
Treatment for neurotoxicity includes stopping any exposure to the toxic substance and supportive therapy to treat the associated symptoms.
Who are the top Neurotoxicity Syndromes Local Doctors?
Elite in Neurotoxicity Syndromes
Paola M. Alberti
Elite in Neurotoxicity Syndromes
Paola M. Alberti
Referral may be required
Via Cadore 48, 
Monza, IT 

Paola Alberti practices practicing medicine in Monza, Italy. Ms. Alberti is rated as an Elite expert by MediFind in the treatment of Neurotoxicity Syndromes. She is also highly rated in 3 other conditions, according to our data. Her clinical expertise encompasses Neurotoxicity Syndromes, Peripheral Neuropathy, Neuralgia, and Colorectal Cancer.

Elite in Neurotoxicity Syndromes
Guido A. Cavaletti
Elite in Neurotoxicity Syndromes
Guido A. Cavaletti
Referral may be required
Monza, IT 

Guido Cavaletti practices practicing medicine in Monza, Italy. Mr. Cavaletti is rated as an Elite expert by MediFind in the treatment of Neurotoxicity Syndromes. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Peripheral Neuropathy, Neurotoxicity Syndromes, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Polyradiculoneuritis, and Islet Cell Transplantation.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Neurotoxicity Syndromes
Andreas A. Argyriou
Elite in Neurotoxicity Syndromes
Andreas A. Argyriou
Referral may be required
General Hospital Of Kos Island, 
Kos, ESYE42, GR 

Andreas Argyriou practices practicing medicine in Kos, Greece. Mr. Argyriou is rated as an Elite expert by MediFind in the treatment of Neurotoxicity Syndromes. He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Neurotoxicity Syndromes, Headache, Migraine, and Peripheral Neuropathy.

View All Doctors
What are the latest Neurotoxicity Syndromes Clinical Trials?
An Exploratory Study on Targeted CD22/CD19 Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy for Enhanced Consolidation Therapy of Standard-risk B-cell Acute Lymphoblastic Leukemia
An Exploratory Study on Targeted CD22/CD19 Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy for Enhanced Consolidation Therapy of Standard-risk B-cell Acute Lymphoblastic Leukemia
Enrollment Status: Recruiting
Publish Date: June 15, 2026
Intervention Type: Biological
Study Phase: Phase 1/Phase 2

Summary: This is a single-center, open-label, single-arm prospective study designed to evaluate the safety, tolerability, and efficacy of dual-target CD22/CD19 chimeric antigen receptor (CAR)-T cell therapy as consolidation treatment in patients with standard-risk B-cell acute lymphoblastic leukemia (B-ALL) in remission. Eligible patients will undergo leukapheresis for CAR-T cell manufacturing, followed by...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Voice as a Digital Biomarker of Neurotoxicity in CAR T-Cell Therapy
Voice as a Digital Biomarker of Neurotoxicity in CAR T-Cell Therapy
Enrollment Status: Recruiting
Publish Date: May 27, 2026
Intervention Type: Diagnostic test

Summary: The purpose of this study is to collect voice recordings and nervous system (neurologic) assessments from people with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM) who are receiving standard treatment with CAR T-cell therapy. Researchers will study whether these voice recordings and assessments are a practical (feasible) way to monitor for immune effector cell-associated neurotoxicity syndro...

View All Clinical Trials